Original paper
Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC
Abstract
In patients (pts) with NSCLC, the efficacy of atezo (anti-PDL1) correlates with PD-L1 expression on tumor cells (TC) and tumor-infiltrating immune cells (IC). We further examined the association between tumor mutation load (ML) and efficacy of atezo in pts with NSCLC. Pretreatment tumor specimens from 454 2L+ NSCLC pts treated on three Ph 2 trials of atezo monotherapy (POPLAR, a trial comparing atezo vs docetaxel (doc); BIRCH and FIR, single-arm...
Paper Details
Title
Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC
Published Date
Oct 1, 2016
Journal
Volume
27
Pages
vi23 - vi23
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History